885592-71-2

Basic information

• Product Name: (2S,3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolane
• Synonyms: (2S,3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolane
• CAS NO: 885592-71-2
• Molecular Weight: 448.559
• Mol File: 885592-71-2.mol

Chemical Properties

• CAS DataBase Reference: (2S,3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolane(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolane(885592-71-2)
• EPA Substance Registry System: (2S,3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolane(885592-71-2)

Safety Data

• Hazardous Substances Data: 885592-71-2(Hazardous Substances Data)

Upstream product

• 885592-70-1 (2S,3R,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxy-3-methyloxolan-3-ol 
• 100-39-0 benzyl bromide 

Downstream Products

• 1314972-33-2 (3R,4R,5R)-3,4-bis(benzyloxy)-5-(benzyloxymethyl)-3-methyl-tetrahydro-furan-2-ol 
• 1040273-60-6 7-((2S,3S,4R,5R)-3,4-bis-(benzyloxy)-5-benzyloxymethyl-3-methyl-tetrahydrofuran-2-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine 
• 917567-08-9 (3R,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxolan-2-one 

Relevant articles and documents

Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides

Synthetic nucleoside analogues characterized by a C–C anomeric linkage form a family of promising therapeutics against infectious and malignant diseases. Herein, C-nucleosides comprising structural variations at the sugar and nucleobase moieties were exam

SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-?-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME

A compound represented by a formula [1D] as shown below (wherein R1A, R1B, R2A, R2B, R3A and R3B represent a hydrogen atom, an optionally substituted C1-6 alkyl group, and the li

THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES

The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents.